Efficacy
DLBCL
SECONDARY
Preliminary efficacy was a secondary endpoint of the study. Response rates in part A were unchanged from those previously reportedOf the 23 patients with R/R DLBCL treated in part B, 15 (65.2%) were evaluable for response (Fig. 